Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Study to Evaluate the Efficacy of a Reduced Starting Dose of Lazertinib (Leclaza) and Preemptive Magnesium Supplementation to Prevent Lazertinib (Leclaza)-Induced Peripheral Neuropathy

NCT07774520 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.

NCT NCT07774520
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07774520 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Study to Evaluate the Efficacy of a Reduced Starting Dose of Lazertinib (Leclaza) and Preemptive Magnesium Supplementation to Prevent Lazertinib (Leclaza)-Induced Peripheral Neuropathy
Lead sponsor
Samsung Medical Center
Phase
Phase 2
Overall status
Recruiting
Start date
May 26, 2026
Completion date
December 31, 2029
Enrollment
1,173 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

egfr mutant, non-small cell lung cancer(nsclc)